Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POVAN (pyrvinium pamoate) is an oral tablet anthelmintic agent indicated for parasitic infections. The drug works by disrupting parasitic metabolism and motility. It is positioned as a treatment option for helminthic infections in patient populations with limited alternatives.
Pre-Launch
Pre-launch stage offers opportunity to build foundational commercial infrastructure, but limited current market data constrains team sizing and resource allocation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
POVAN's pre-launch status means career opportunities are currently limited, but Pfizer's backing provides stability for those joining at market entry. Early-stage roles will focus on market access, regulatory execution, and launch infrastructure rather than mature product management.
Brand ManagerField Sales Representative
Worked on POVAN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.